Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
EFFECT
Notice of effectiveness
25 Mar 24
424B5
Prospectus supplement for primary offering
22 Mar 24
S-8
Registration of securities for employees
13 Mar 24
S-3
Shelf registration
13 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January
13 Mar 24
8-K
Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4
4 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Results of Operations and Financial Condition
8 Nov 23
8-K
Entry into a Material Definitive Agreement
20 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Results of Operations and Financial Condition
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Other Events
7 Jun 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Announced launch and commercial availability of FUROSCIX® on February 20th
10 May 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
S-8
Registration of securities for employees
22 Mar 23
S-8
Registration of securities for employees
22 Mar 23
10-K
2022 FY
Annual report
22 Mar 23
8-K
Financial Results and Provides Business Update
22 Mar 23
8-K
Other Events
10 Mar 23
8-K
Departure of Directors or Certain Officers
19 Dec 22
424B5
Prospectus supplement for primary offering
23 Nov 22
8-K
Other Events
23 Nov 22
FWP
Free writing prospectus
22 Nov 22
424B5
Prospectus supplement for primary offering
21 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Entered into a secured debt financing agreement for up to $100 million with funds managed by Oaktree
9 Nov 22
8-K
Entry into a Material Definitive Agreement
14 Oct 22
8-K
Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act
9 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpoints
12 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 22
10-Q
2022 Q1
Quarterly report
16 May 22
8-K
Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved
16 May 22
8-K
Company preparing for Q4 commercial launch, if approved
16 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
Latest ownership filings
SC 13G/A
BlackRock Inc.
5 Apr 24
4
John H Tucker
2 Apr 24
SC 13G/A
5AM Ventures IV, L.P.
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
Rubric Capital Management LP
12 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G
BlackRock Inc.
2 Feb 24
SC 13G/A
Cowen Financial Products LLC
2 Feb 24
4
Rachael Nokes
22 Jan 24
4
John H Tucker
22 Jan 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
12 Jan 24
4
Rachael Nokes
3 Jan 24
4
John H Tucker
3 Jan 24
4
Minnie Baylor-Henry
8 Jun 23
4
Mette Kirstine Agger
8 Jun 23
4
KLAUS R DR VEITINGER
8 Jun 23
4
William Tober Abraham
8 Jun 23
4
Frederick M. Hudson
8 Jun 23
4
Sara Bonstein
8 Jun 23
4
Jack A. Khattar
8 Jun 23
4
LEONARD D SCHAEFFER
8 Jun 23
SC 13G
MILLENNIUM MANAGEMENT LLC
13 Mar 23
SC 13G
Cowen Financial Products LLC
27 Feb 23
SC 13G/A
HIRSCHMAN ORIN
15 Feb 23
SC 13G/A
5AM Ventures IV, L.P.
14 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
4
John H Tucker
23 Jan 23
4
Rachael Nokes
23 Jan 23
4
Rachael Nokes
19 Dec 22
4
Change in insider ownership
29 Nov 22
SC 13D/A
ORBIMED ADVISORS LLC
29 Nov 22
SC 13G
HIRSCHMAN ORIN
25 Nov 22
4
SCOTT M ROCKLAGE
11 Oct 22
4
John H Tucker
11 Oct 22
4
SCOTT M ROCKLAGE
8 Sep 22
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
15 Aug 22
4
Sara Bonstein
15 Jun 22
4
Frederick M. Hudson
15 Jun 22
4
KLAUS R DR VEITINGER
15 Jun 22
4
Minnie Baylor-Henry
15 Jun 22